Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER Stock Report

Market Cap: Ft1.9t

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Valuation

Is RICHTER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RICHTER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RICHTER (HUF10480) is trading below our estimate of fair value (HUF24276.45)

Significantly Below Fair Value: RICHTER is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RICHTER?

Key metric: As RICHTER is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RICHTER. This is calculated by dividing RICHTER's market cap by their current earnings.
What is RICHTER's PE Ratio?
PE Ratio9x
EarningsFt211.64b
Market CapFt1.91t

Price to Earnings Ratio vs Peers

How does RICHTER's PE Ratio compare to its peers?

The above table shows the PE ratio for RICHTER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average68.6x
600518 Kangmei Pharmaceutical
142.1xn/aCN¥36.3b
ALK B ALK-Abelló
45.4x21.5%DKK 35.7b
002294 Shenzhen Salubris Pharmaceuticals
59.9x15.3%CN¥36.6b
000423 Dong-E-E-JiaoLtd
26.7x15.0%CN¥40.6b
RICHTER Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
9x14.2%Ft1.9t

Price-To-Earnings vs Peers: RICHTER is good value based on its Price-To-Earnings Ratio (9x) compared to the peer average (68.6x).

Price to Earnings Ratio vs Industry

How does RICHTER's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
RICHTER 9.0xIndustry Avg. 19.3xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RICHTER is good value based on its Price-To-Earnings Ratio (9x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is RICHTER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RICHTER PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RICHTER's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RICHTER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentFt10,480.00
Ft12,149.33
+15.9%
9.6%Ft13,200.00Ft9,435.00n/a9
Dec ’25Ft10,400.00
Ft12,104.89
+16.4%
9.5%Ft13,200.00Ft9,435.00n/a9
Nov ’25Ft10,840.00
Ft11,893.78
+9.7%
9.8%Ft13,124.00Ft9,435.00n/a9
Oct ’25Ft11,220.00
Ft11,893.78
+6.0%
9.8%Ft13,124.00Ft9,435.00n/a9
Sep ’25Ft10,770.00
Ft11,743.22
+9.0%
9.7%Ft13,124.00Ft9,435.00n/a9
Aug ’25Ft10,230.00
Ft11,800.33
+15.4%
10.7%Ft13,400.00Ft9,435.00n/a9
Jul ’25Ft9,690.00
Ft11,800.33
+21.8%
10.7%Ft13,400.00Ft9,435.00n/a9
Jun ’25Ft9,100.00
Ft11,800.33
+29.7%
10.7%Ft13,400.00Ft9,435.00n/a9
May ’25Ft9,340.00
Ft11,671.11
+25.0%
9.9%Ft13,400.00Ft9,435.00n/a9
Apr ’25Ft9,260.00
Ft11,515.56
+24.4%
10.4%Ft13,400.00Ft9,435.00n/a9
Mar ’25Ft9,625.00
Ft11,330.56
+17.7%
10.9%Ft13,400.00Ft9,435.00n/a9
Feb ’25Ft9,765.00
Ft10,903.89
+11.7%
10.2%Ft12,990.00Ft9,435.00n/a9
Jan ’25Ft8,750.00
Ft10,631.11
+21.5%
8.0%Ft12,000.00Ft9,435.00n/a9
Dec ’24Ft8,820.00
Ft10,631.11
+20.5%
8.0%Ft12,000.00Ft9,435.00Ft10,400.009
Nov ’24Ft8,475.00
Ft10,542.22
+24.4%
9.1%Ft12,600.00Ft9,435.00Ft10,840.009
Oct ’24Ft8,915.00
Ft10,426.67
+17.0%
10.0%Ft12,600.00Ft9,260.00Ft11,220.009
Sep ’24Ft8,965.00
Ft10,426.67
+16.3%
10.0%Ft12,600.00Ft9,260.00Ft10,770.009
Aug ’24Ft8,935.00
Ft10,203.33
+14.2%
11.2%Ft12,600.00Ft8,900.00Ft10,230.009
Jul ’24Ft8,420.00
Ft10,203.33
+21.2%
11.2%Ft12,600.00Ft8,900.00Ft9,690.009
Jun ’24Ft8,600.00
Ft10,203.33
+18.6%
11.2%Ft12,600.00Ft8,900.00Ft9,100.009
May ’24Ft8,170.00
Ft10,123.33
+23.9%
11.8%Ft12,600.00Ft8,600.00Ft9,340.009
Apr ’24Ft7,325.00
Ft10,166.25
+38.8%
13.0%Ft12,800.00Ft8,600.00Ft9,260.008
Mar ’24Ft7,585.00
Ft10,966.25
+44.6%
14.4%Ft14,000.00Ft9,260.00Ft9,625.008
Feb ’24Ft8,145.00
Ft10,853.75
+33.3%
15.4%Ft14,000.00Ft8,820.00Ft9,765.008
Jan ’24Ft8,300.00
Ft10,834.75
+30.5%
16.9%Ft14,000.00Ft8,783.00Ft8,750.008
Dec ’23Ft8,500.00
Ft10,482.57
+23.3%
16.0%Ft14,000.00Ft8,783.00Ft8,820.007

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 02:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon MatherBarclays
Samuel EnglandBerenberg
Victoria LambertBerenberg